ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aptinyx raises funds for neurologic drugs

by Michael McCoy
January 1, 2018 | APPEARED IN VOLUME 96, ISSUE 1

Aptinyx has completed a $70 million series B fundraising intended to advance its pipeline of drugs that treat neurologic disorders by modulating N-methyl-d-aspartate receptors. One of those compounds, NYX-2925, is in Phase II clinical trials involving people with diabetes-related pain. Aptinyx was formed in 2015 when Allergan spun off the drug discovery operations of Naurex, a company it acquired.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment